The p53 codon 72 (Arg72Pro) polymorphism is associated with the degree of insulin resistance in type 2 diabetic subjects: a cross-sectional study
- PMID: 23269546
- DOI: 10.1007/s00592-012-0450-x
The p53 codon 72 (Arg72Pro) polymorphism is associated with the degree of insulin resistance in type 2 diabetic subjects: a cross-sectional study
Abstract
Tumor suppressor protein p53 has been demonstrated to regulate genes involved in energy generating metabolic pathways and apoptosis. To date, a new field of research is the involvement of TP53 codon 72 (Arg72Pro) polymorphism in the diabetic disease. The aim of this study was to evaluate whether the genotype and the related genetic models of Arg72Pro polymorphism of TP53 (rs1042522) are associated with insulin resistance and its metabolic parameters in diabetic and non-diabetic subjects. We examined 335 type 2 diabetic patients (65.5 ± 8.4 years) and 367 non-diabetic subjects (60.5 ± 11.7 years). The results were validated in a validation sample consisting of 199 type 2 diabetic (66.2 ± 8.5 years) and 224 non-diabetic subjects (61.2 ± 12.7 years). In the study sample, the analysis of covariance, adjusted for the effects of age, gender and BMI, showed a significant genotype-diabetes effect on insulin resistance evaluated by HOMA-IR (p = 0.038). This result was mediated by variations in fasting plasma insulin (p = 0.027), as no TP53 genotype-diabetes effects were detected for fasting plasma glucose. In particular, in the diabetic subjects, Pro/Pro genotype was associated with lower values of HOMA-IR with respect to Arg/Arg (p = 0.013) and Arg/Pro (p = 0.006) carriers. No difference in HOMA-IR between diabetic and non-diabetic Pro/Pro carriers was found. Significant recessive model-diabetes interaction effects on fasting insulin and HOMA-IR adjusted for age, sex and BMI were found (p = 0.007 and p = 0.029, respectively). Linear regression analyses, based on the assumption of an additive genetic model adjusted for age, sex and BMI, highlight p53 gene-diabetes interaction effects on fasting insulin (β = -1.27; p = 0.001) and HOMA-IR (β = -0.22; p = 0.006). The results of statistical analyses on fasting insulin and HOMA-IR were all confirmed in the validation sample. Furthermore, the logistic regression models confirmed that the effect of HOMA-IR levels on diabetes was moderated by Pro/Pro genotype in both study and validation samples (OR = 0.29, p = 0.034, 95 % CI = 0.09-0.91, OR = 0.37, p = 0.035, 95 % CI = 0.15-0.93, respectively). Our findings suggest that p53 codon 72 (Arg72Pro) polymorphism influences insulin resistance in type 2 diabetic patients independently of body mass.
Similar articles
-
The role of the p53 tumor suppressor in metabolism and diabetes.J Endocrinol. 2016 Nov;231(2):R61-R75. doi: 10.1530/JOE-16-0324. Epub 2016 Sep 9. J Endocrinol. 2016. PMID: 27613337 Free PMC article. Review.
-
Interleukin-6-174 G > C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients.Diabetes Res Clin Pract. 2006 Mar;71(3):299-305. doi: 10.1016/j.diabres.2005.07.007. Epub 2005 Sep 2. Diabetes Res Clin Pract. 2006. PMID: 16140413
-
HOMA-estimated insulin resistance is associated with hypertension in Iranian diabetic and non-diabetic subjects.Clin Exp Hypertens. 2008 Jul;30(5):297-307. doi: 10.1080/10641960802269919. Clin Exp Hypertens. 2008. PMID: 18633753
-
Association of the + 45T>G adiponectin gene polymorphism with insulin resistance in non-diabetic Saudi women.Gene. 2013 Nov 1;530(1):158-63. doi: 10.1016/j.gene.2013.07.003. Epub 2013 Aug 17. Gene. 2013. PMID: 23958652
-
Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future.Drug Discov Ther. 2015 Dec;9(6):380-5. doi: 10.5582/ddt.2015.01207. Drug Discov Ther. 2015. PMID: 26781921 Review.
Cited by
-
Is p53 Involved in Tissue-Specific Insulin Resistance Formation?Oxid Med Cell Longev. 2017;2017:9270549. doi: 10.1155/2017/9270549. Epub 2017 Jan 17. Oxid Med Cell Longev. 2017. PMID: 28194257 Free PMC article. Review.
-
Control of metabolism by p53 - Cancer and beyond.Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):32-42. doi: 10.1016/j.bbcan.2018.06.001. Epub 2018 Jun 5. Biochim Biophys Acta Rev Cancer. 2018. PMID: 29883595 Free PMC article. Review.
-
Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk.Cancers (Basel). 2020 Sep 1;12(9):2472. doi: 10.3390/cancers12092472. Cancers (Basel). 2020. PMID: 32882831 Free PMC article.
-
Therapeutic Role of Curcumin in Diabetes: An Analysis Based on Bioinformatic Findings.Nutrients. 2022 Aug 8;14(15):3244. doi: 10.3390/nu14153244. Nutrients. 2022. PMID: 35956419 Free PMC article.
-
The role of the p53 tumor suppressor in metabolism and diabetes.J Endocrinol. 2016 Nov;231(2):R61-R75. doi: 10.1530/JOE-16-0324. Epub 2016 Sep 9. J Endocrinol. 2016. PMID: 27613337 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous